Knee osteoarthritis
Conditions
Interventions
Intraarticular administration of S-ADSCs using a 21G needle with echo guide. Dosing a full of one container in one injection. The cell suspension contains about 42,000 S-ADSCs.
Sponsors
Sobajima Satoshi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: -Patients with dysfunction associated with osteoarthritis -Over 20 years old when obtaining consent -No improvement in standard conservative therapy for insurance indication -Don't wish to perform artificial joint replacement or osteotomy -Obtain written consent sufficient explanation about this study -Able to comply with a fixed schedule
Exclusion criteria
Exclusion criteria: -Patients who have difficulty with subcutaneous liposuction -Patients with cancer -Patients who are using anti-cancer drugs, biologics or immunosuppressants -Patients with active infection -Patients who have recieved this treatment within a month -Patients with serious complicaitons such as heart disease, liver diseaes, lung disease, kidny disease, bleeding tendency, uncontroled diabetes, hypertension, etc. -Patients with a history of drug sensitivity to anesthetics -Other patients judged inappropriate by doctors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical score evaluation such as WOMAC, JKOM, KOOS (4 weeks, 12 weeks, and 24 weeks after treatment) MRI image evaluation (24 weeks after treatment) | — |
Countries
Japan
Contacts
Public ContactMisako Fujii
Sobajima Clinic
Outcome results
None listed